This partnership combines the EOPatch, a third-party continuous glucose monitor (CGM) and Diabeloop’s automated insulin delivery algorithm. They all integrate into Diabeloop’s currently under-development smartphone app.
Paris-based Diabeloop said in a news release that they also plan to integrate EOPatch into its DBLG1 system. This would integrate the algorithm into a dedicated handset.
Get the full story at our sister site, Drug Delivery Business News.
This partnership combines the EOPatch, a third-party continuous glucose monitor (CGM) and Diabeloop’s automated insulin delivery algorithm. They all integrate into Diabeloop’s currently under-development smartphone app.
Paris-based Diabeloop said in a news release that they also plan to integrate EOPatch into its DBLG1 system. This would integrate the algorithm into a dedicated handset.
Get the full story at our sister site, Drug Delivery Business News.
Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low.
Get the full story at our sister site, Drug Delivery Business News.
Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020.
Get the full story at our sister site, Drug Delivery Business News.
Diabeloop announced today that it raised approximately $74.9 million (€70 million) in a Series C financing round.
LBO France, a private equity player, led the financing round, while Terumo — with which Diabeloop has partnered since 2020 — also participated in the round.
Get the full story at our sister site, Drug Delivery Business News.
Diabeloop announced today that it raised approximately $74.9 million (€70 million) in a Series C financing round.
LBO France, a private equity player, led the financing round, while Terumo — with which Diabeloop has partnered since 2020 — also participated in the round.
Get the full story at our sister site, Drug Delivery Business News.
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.
From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.
Here are five of the biggest stories to come out of ATTD 2022:
Dexcom’s G7 is accurate in pediatric T1D patients
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.
The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.
Get the full story at our sister site, Drug Delivery Business News.
Diabeloop announced today that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system.
Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia.
Get the full story at our sister site, Drug Delivery Business News.
Diabeloop announced today that it leveraged its diabetes management software to integrate insulin pens into its hybrid closed-loop system.
Paris-based Diabeloop’s DBL-4pen, a unique app, offers new opportunities for the personalized management of people with type 1 and type 2 diabetes.
Get the full story at our sister site, Drug Delivery Business News.
Diabeloop announced that it entered into an agreement with Terumo with eyes on bringing automated insulin delivery solutions to Europe.
Paris-based Diabeloop’s automated insulin delivery (AID) system automates and personalizes the treatment of insulin-dependent diabetes and contributes to reducing the mental burden associated with the metabolic disease.
Get the full story at our sister site, Drug Delivery Business News.
World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.
This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.
Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.
However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:
Next>>World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.
This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.
Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.
However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:
Next>>